Compounds > 5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide
Page last updated: 2024-09-03

5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide and Disease Exacerbation

5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide has been researched along with Disease Exacerbation in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Budhiraja, RD; Garg, A; Katyal, T1

Other Studies

1 other study(ies) available for 5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide and Disease Exacerbation

ArticleYear
Combination of daidzein, hemin and bms182874 halts the progression of diabetes-induced experimental nephropathy.
    Endocrine, metabolic & immune disorders drug targets, 2013, Volume: 13, Issue:2

    Topics: Animals; Cytoprotection; Dansyl Compounds; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Drug Combinations; Drug Evaluation, Preclinical; Hemin; Isoflavones; Kidney; Male; Rats; Rats, Wistar; Streptozocin

2013